COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II...
59 insider sale filings on record · latest filing 2024-09-27.
No open-market insider purchases (SEC Form 4 code P) on record for CMPS.